Last reviewed · How we verify
NCT00459693
PET Evaluation of Brain Peripheral Benzodiazepine Receptors Using [11C]PBR28 in HIV-Seropositive Patients With (MCMD)
NA trial testing [11C]PBR28 in HIV-Dementia in 40 participants. Terminated before completion.
6 April 2014
Quick facts
| Lead sponsor | National Institute of Mental Health (NIMH) |
|---|---|
| Phase | NA |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Primary purpose | treatment |
| Enrollment | 40 |
| Start date | 9 April 2007 |
| Primary completion | 6 April 2014 |
| Estimated completion | 6 April 2014 |
| Sites | 1 location across United States |
Drugs / interventions tested
- [11C]PBR28
Conditions studied
- HIV-Dementia — all drugs for HIV-Dementia →
- HIV-Associated Cognitive Motor Complex — all drugs for HIV-Associated Cognitive Motor Complex →
- AIDS Encephalopathy — all drugs for AIDS Encephalopathy →
- AIDS Dementia Complex — all drugs for AIDS Dementia Complex →
Sponsor
National Institute of Mental Health (NIMH)
Who can join
Adults 18 to 50, any sex, with HIV-Dementia or HIV-Associated Cognitive Motor Complex. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this protocol is to measure a receptor in the brain using positron emission tomography (PET) that is involved in inflammation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The changing landscape in translocator protein (TSPO) function.
Selvaraj V, Stocco DM. · · 2015 · cited 97× · PMID 25801473 · DOI 10.1016/j.tem.2015.02.007
Verify or expand the search:
- PubMed search for NCT00459693
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of [11C]PBR28
Trials testing the same drug.
- NCT04398719 — CBD-Microglia PET Study · EARLY_PHASE1 · recruiting
- NCT04274998 — Neuroinflammation Imaging in AD · EARLY_PHASE1 · active not recruiting
Other National Institute of Mental Health (NIMH) trials
Trials by the same sponsor.
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT05652465 — Transcranial Magnetic Stimulation for Youth With Treatment-Resistant Major Depressive Disorder · Phase 2 · suspended
- NCT07027839 — Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B) · Phase 1 · recruiting
- NCT06920628 — PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 In · Phase 1 · recruiting
- NCT06874205 — Assessment of 11C-JMJ-129 for Imaging PDE4D in Brain and Whole Body of Healthy Volunteers · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT00459693 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Institute of Mental Health (NIMH)
- Last refreshed: 10 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00459693.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing